Markets
NVS

Novartis Launches Zero-Profit COVID-19 Medicine Portfolio To 79 Countries - Quick Facts

(RTTNews) - Novartis (NVS) announced the launch of first-of-its-kind not-for-profit portfolio of medicines for symptomatic treatment of COVID-19.

The company noted that its portfolio of 15 generic and over-the-counter or OTC medicines from Sandoz division addresses urgent unmet needs of low- and lower-middle-income countries to treat patients with COVID-19 symptoms.

Further, the company has planned to sell its portfolio at zero-profit to governments, Non-Governmental Organizations or NGOs and other institutional customers in up to 79 eligible countries during the pandemic and until a vaccine or curative treatment is available.

The following medicines are included in the Novartis COVID-19 Response Portfolio: Amoxicillin, Ceftriaxone, Clarithromycin, Colchicine, Dexamethasone, Dobutamine, Fluconazole, Heparin, Levofloxacin, Loperamide, Pantoprazole, Prednisone, Prednisolone, Salbutamol, Vancomycin.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

NVS

Latest Markets Videos

    RTTNews

    Founded in the late 1990s by Andrew Mariathasan in New York, with the goal of covering Wall Street for a new generation of investors, RTTNews has expanded steadily over the years to become a trusted provider of content for a wide array of subjects across several platforms. RTT's Financial Newswire is relied upon by some of the world's largest financial institutions, including banks, brokerages, trading platforms and financial exchanges.

    Learn More